Insurer limited choices are clearly based on financial incentives between the manufacturer and insurers. Like Dr. Popes evidenced based leveling, the new ACR RA treatment guidelines allow equal entry and use by other MOA biologics. Hence your best defense for earlier use of other non-TNF biologics would be the reference the authority document - the 2015 ACR RA treatment guidelines!